EFFECT OF LOSARTAN ON SERUM INTERLEUKIN-6 (IL-6) LEVELS IN HYPERTENSIVE PATIENTS WITH ASYMPTOMATIC HYPERURICEMIA AT DR. MOHAMMAD HOESIN HOSPITAL PALEMBANG

Abstract

Background: Hypertension and hyperuricemia are factors related to cardiovascular disease risk. Hyperuricemia is found in approximately 25% patients with hypertension while hypertension is found in 30% patients with hyperuricemia or gout. The link between hypertension and hyperuricemia theoretically explained by the effect of uric acid on renal and vascular smooth muscle cells. Hyperuricemia leads to inflammation and endothelial dysfunction. Losartan is an angiotensin renin blocker that has other effects as an anti-inflammatory and uricosuric agent. Objective: This study to determine the effect of losartan on serum IL-6 levels in hypertensive patients with asymptomatic hyperuricemia in DR. Mohammad Hoesin Hospital Palembang. Method: This study is a clinical trial before and after design. This research was conducted in the Internal Medicine Dr. Mohammad Hoesin (RSMH) Hospital Palembang began from March to August 2013. Result: Research subjects were 30 patients with 53.3% men and 46.7% women. Effect of losartan on reduction in systolic and diastolic blood pressure (146.00 ± 4.98/88.67 ± 3.45 to 126.67 ± 7.39/79.00 ± 4.02 mmHg, p = 0.000), uric acid serum (8.57 ± 1.26 to 5.94 ± 1.57 mg/dl, p = 0.000), 24-hour urinary uric acid (369.03 ± 146.49 to 510, 67 ± 231.70 mg/24 hours, p = 0.001), IL-6 serum levels is 3.27(0.48–19.8) to 2.66(0.3–17.83) pg/ ml (p = 0.015) by administration losartan potassium tablet 50 mg once daily for eight weeks. Conclusion: Losartan decreased interleukin-6, blood pressure, serum uric acid levels and increased urinary excretion of uric acid 24 hours in hypertensive patients with asymptomatic hyperuricemia significantly.